Comparative effectiveness of CDK4/6 inhibitors in metastatic breast cancer: using the target trial emulation framework to investigate overall survival in routine care [0.03%]
靶向试验模拟框架下的CDK4/6抑制剂在转移性乳腺癌中的疗效比较：常规治疗中总生存期的研究
Adam M Brufsky,Richard S Finn,Otto Metzger et al.
Adam M Brufsky et al.
Purpose: Cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) plus aromatase inhibitor (AI) is the recommended first-line treatment for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic bre...
Comparative Study
Breast cancer research and treatment. 2026 Mar 7;216(2):22. DOI:10.1007/s10549-026-07935-3 2026
Comparing infectious risk of Trastuzumab-deruxtecan to Trastuzumab-emtansine in patients with breast cancer [0.03%]
比较乳腺癌患者T-DMB与T-DM1的感染风险
Scott Gayfield,Jianing Ma,Michael Waleski et al.
Scott Gayfield et al.
Purpose: Trastuzumab-deruxtecan (T-DXd) is an antibody-drug conjugate (ADC) that revolutionized the treatment approach for breast cancer. However, the infectious risk associated with T-DXd is unknown. Here, we evaluate th...
Comparative Study
Breast cancer research and treatment. 2026 Mar 7;216(2):23. DOI:10.1007/s10549-026-07937-1 2026
A phase II study of atezolizumab in combination with stereotactic radiation for patients with triple-negative breast cancer and brain metastasis [0.03%]
阿特珠单抗联合立体定向放疗治疗三阴性乳腺癌脑转移患者II期研究
Antonio Giordano,Noah Graham,Ayal A Aizer et al.
Antonio Giordano et al.
Purpose: Triple-negative breast cancer (TNBC) patients with brain metastases have a poor prognosis and limited treatment options. Preclinical and clinical evidence suggests that radiotherapy may act synergistically with i...
Real-world second- and third-line progression-free survival after progression on first-line CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer by PAM50 intrinsic subtype: the SOLTI-1801 CDK-PREDICT study [0.03%]
PAM50固有亚型影响HR+/HER2-转移性乳腺癌一线使用CDK4/6i后二线和三线的无进展生存：SOLTI-1801 CDK-PREDICT研究
Pablo Tolosa,Isabel García-Fructuoso,Tomás Pascual et al.
Pablo Tolosa et al.
Purpose: Estrogen receptor-positive (ER+), HER2-negative (HER2-) metastatic breast cancer (MBC) shows variable outcomes after first-line CDK4/6 inhibitors (CDK4/6i) plus endocrine therapy (ET). The prognostic role of PAM5...
Observational Study
Breast cancer research and treatment. 2026 Feb 28;216(2):21. DOI:10.1007/s10549-026-07931-7 2026
Effect of a supervised intermittent exercise program on insomnia in breast cancer patients undergoing chemotherapy [0.03%]
化疗乳腺癌患者的间歇运动干预对失眠的影响
Chloé Drozd,Elsa Curtit,Quentin Jacquinot et al.
Chloé Drozd et al.
Background: Patients with localized breast cancer receiving adjuvant chemotherapy often experience sleep disturbances, especially insomnia, which significantly impacts quality of life. This study primarily aimed to evalua...
Baseline and early postoperative bioimpedance spectroscopy and perometry measurements in patients treated for breast cancer: insights from a prospective screening program [0.03%]
乳腺癌治疗患者的基线和早期术后生物阻抗谱和体构成像测量：来自前瞻性筛查计划的见解
Alexa J Taghian,Mahek Aggarwal,Amy M Shui et al.
Alexa J Taghian et al.
Purpose: To describe bioimpedance spectroscopy (BIS) L-Dex values at breast cancer (BC) diagnosis and within the first year post-surgery in a cohort prospectively screened for breast cancer-related lymphedema (BCRL). We a...
Prognostic significance of circulating tumor DNA in early breast cancer: a systematic review and meta-analysis [0.03%]
早期乳腺癌循环肿瘤DNA的预后意义：系统评价和meta分析
L Sisca,M G Polito,M Silletta et al.
L Sisca et al.
Background: Circulating tumor DNA (ctDNA) has emerged as a promising noninvasive biomarker for monitoring minimal residual disease (MRD) and predicting recurrence in early-stage breast cancer (EBC). Despite growing intere...
Ovarian function suppression decision-making and uptake in premenopausal women with breast cancer: a mixed methods analysis [0.03%]
预判和接受乳腺癌治疗的卵巢功能抑制决策：定性和定量分析相结合的方法
N L Henry,L K Monkman,K Griffith et al.
N L Henry et al.
Purpose: Ovarian function suppression (OFS) reduces the risk of recurrence of hormone receptor-positive breast cancer but increases the likelihood of toxicity and nonpersistence with endocrine therapy. In addition, rates ...
Impact of immune-related adverse events on response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: a single-institution retrospective study [0.03%]
免疫相关不良事件对三阴性乳腺癌新辅助化疗免疫治疗疗效影响的单中心回顾性研究
Michelle Sterpi,Nechama Dreyfus,Yungtai Lo et al.
Michelle Sterpi et al.
Purpose: Immune-related adverse events (irAEs) have emerged as a potential surrogate marker for immunotherapy response across tumor types. We evaluated the association between irAEs and pathologic complete response (pCR) ...
Investigating initial patterns of progression on first-line treatment in patients with de novo metastatic breast cancer [0.03%]
新发转移性乳腺癌患者一线治疗中疾病进展的初步模式研究
Emily Huber,Gaorav P Gupta,Ryan Morse et al.
Emily Huber et al.
Purpose: De novo metastatic breast cancer (dnMBC), defined as stage IV disease at initial diagnosis, comprises 6-10% of all metastatic breast cancer cases. Despite therapeutic advances, the unique clinical course of dnMBC...